GlassScriptPhysician profile
Martha L Pickrell
NPI 1033128582
$2,993.36
in general payments reported to CMS, 2019-2025
28 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $679 · 2023: $812 · 2024: $538 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $694.80 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $444.60 | 2021-2025 | |
| Lilly USA, LLC | $338.91 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $252.47 | 2021-2025 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $152.38 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.45 | 2021-2024 | Stiolto Respimat, Jardiance, Tradjenta |
| Pfizer INC. | $146.10 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $82.88 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $64.81 | 2021-2025 | Breztri |
| Astellas Pharma US INC | $57.72 | 2022-2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $56.56 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.43 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $48.09 | 2021 | |
| Upsher-Smith Laboratories LLC | $45.53 | 2021 | |
| Edwards Lifesciences Corporation | $44.27 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $42.18 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $40.94 | 2022 | |
| Esperion Therapeutics, INC. | $40.09 | 2021 | |
| Collegium Pharmaceutical, INC. | $36.57 | 2022 | |
| Currax Pharmaceuticals LLC | $32.06 | 2021 | |
| Amarin Pharma, INC. | $31.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $25.85 | 2021 | |
| Dynavax Technologies Corporation | $19.39 | 2022 | |
| Abbott Laboratories | $17.89 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.87 | 2024 | Rexulti |
| Heartflow, INC. | $15.89 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $14.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Pickrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.